Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme - A Review of Trials

被引:0
|
作者
Pruthi, Deep Shankar [1 ]
Nagpal, Puneet [1 ]
Pandey, Manish [1 ]
机构
[1] Act Canc Hosp, Dept Radiat Oncol, A-4, New Delhi, India
来源
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY | 2021年 / 5卷 / 03期
关键词
Adjuvant; Glioblastoma Multiforme; Extended duration; Temozolomide; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; PROLONGED TEMOZOLOMIDE; OPEN-LABEL; RADIOTHERAPY; CONCOMITANT; SURVIVAL; THERAPY;
D O I
10.14744/ejmo.2021.20733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 50 条
  • [1] The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
    Alimohammadi, Ehsan
    Bagheri, Seyed Reza
    Taheri, Shahram
    Dayani, Maliheh
    Abdi, Alireza
    ONCOLOGY REVIEWS, 2020, 14 (01) : 17 - 22
  • [2] Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
    Urgoiti, Gloria B. Roldan
    Singh, Amitabh D.
    Easaw, Jacob C.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 108 (01) : 173 - 177
  • [3] Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
    Gloria B. Roldán Urgoiti
    Amitabh D. Singh
    Jacob C. Easaw
    Journal of Neuro-Oncology, 2012, 108 : 173 - 177
  • [4] Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma
    Gupta, Tejpal
    Selvarajan, Jeevi Mona Priyadharshni
    Kannan, Sadhana
    Menon, Nandini
    Dasgupta, Archya
    Chatterjee, Abhishek
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [5] Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
    Wang, Nan
    Huang, Renxuan
    Yang, Kunmeng
    He, Yichun
    Gao, Yufei
    Dong, Delu
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (03) : 893 - 912
  • [6] Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Systematic Review
    Yang, Li-Juan
    Zhou, Chang-Fu
    Lin, Zhi-Xiong
    CANCER INVESTIGATION, 2014, 32 (02) : 31 - 36
  • [7] The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme
    Brzozowska, Anna
    Torun, Anna
    Mazurkiewicz, Maria
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 24 (02): : 279 - 287
  • [8] Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma
    Pitz, M. W.
    Lipson, M.
    Hosseini, B.
    Lambert, P.
    Guilbert, K.
    Lister, D.
    Schroeder, G.
    Jones, K.
    Mihalicioiu, C.
    Eisenstat, D. D.
    CURRENT ONCOLOGY, 2012, 19 (06) : 308 - 314
  • [9] A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
    Attarian, Fahimeh
    Taghizadeh-Hesary, Farzad
    Fanipakdel, Azar
    Javadinia, Seyed Alireza
    Porouhan, Pejman
    PeyroShabany, Babak
    Fazilat-Panah, Danial
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis
    Gupta, Tejpal
    Talukdar, Riddhijyoti
    Kannan, Sadhana
    Dasgupta, Archya
    Chatterjee, Abhishek
    Patil, Vijay
    NEURO-ONCOLOGY PRACTICE, 2022, 9 (05) : 354 - 363